What does Cagrilintide do? Benefits and evidence

An unapproved weekly amylin analogue with weight-loss trials and common stomach symptoms.

Also called: AM833, NNC0174-0833, NN9838, Cagri.

Amylin analogues · Long-acting amylin analogue; amylin and calcitonin receptor agonist.

Cagrilintide copies the fullness hormone amylin. Human trials studied it alone and with semaglutide. It reduced weight, but it has no approved dosing label as of October 18, 2026. Nausea, bowel symptoms and injection-site reactions are common; long-term safety and online-vial quality remain uncertain.

  • In a large trial, all five weekly doses tested led to more weight loss than placebo. (Studied in a trial)
  • In trials, adding it to semaglutide led to more weight loss than semaglutide alone. (Studied in a trial)
  • In a small diabetes trial, blood sugar improved, but this is less proven than its use with semaglutide. (Studied in a trial)
  • Some people report less hunger, even at small doses; others report no effect. (Reported by users)

Uses in the sources

  • Studied alone for weight loss in adults with obesity or overweight with related health conditions. (Studied in a trial) (source)
  • A small diabetes trial found glucose improvement; standalone diabetes benefit is less established than combination benefit. (Studied in a trial) (source)

Related to Cagrilintide

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.